Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

International Stem Cell: Q119 Results

By Edison Market OverviewJun 05, 2019 08:05AM ET
www.investing.com/analysis/international-stem-cell-q119-results-200428552
International Stem Cell: Q119 Results
By Edison   |  Jun 05, 2019 08:05AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
ISCO
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

International Stem Cell Corp (OTC:ISCO) reported Q119 revenues of $2.2m, down 15.8% compared with Q118 as both the biomedical and cosmetic businesses exhibited weakness. Biomedical revenues, which had been up 78.4% in 2018, were down 16.2% for the quarter. The profitability of the biomedical business also declined as revenues fell but expenses grew. The segment provided $0.8m in profits in Q118, but only $0.3m this quarter.

Year End Revenue
Year End Revenue

Pharma & Biotech
Pharma & Biotech

Share Price Performance
Share Price Performance

Business description

International Stem Cell is currently commercializing biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells. It has also recently completed enrolment in its Phase I trial for its lead pipeline program, a cell therapy treatment for Parkinson’s disease.

Sales take a breather in key commercial operations

ISCO’s commercial operations leverage its human parthenogenetic stem cell (hpSC) technology and generate revenues to partially offset R&D spending for therapeutic development. Lifeline Skin Care (LSC) develops and sells skincare products and Lifeline Cell Technology (LCT) produces human cell culture products for testing. Together they generated $11.1m in sales in 2018, up 48.7% compared with last year, and provided $2.4m in operating profit, which was used to fund R&D. This quarter, however, sales were $2.2m and operating profit was only $0.2m.

Parkinson’s disease trial fully enrolled

The company recently announced the full enrolment of its Phase I trial of ISC-hpNSC in Parkinson’s disease (PD). As a reminder, patients in the study are being treated in three cohorts with 30m, 50m and 70m stem cells, delivered via intracranial injection. The single-arm, open-label study is being conducted at the Royal Melbourne Hospital in Australia. Clinical assessments are scheduled at six and 12 months following surgery with complete data expected in H120.

R&D expenses expected to fall over the near term

As the treatment phase of the Phase I trial in PD patients has been completed the company has stated that clinical trial expenses should ‘significantly decrease’. We now expect a decrease to $2m in 2019 from $2.4m in 2018, with some room to fall further. We currently expect expenses to re-accelerate in 2020 after PD data is available and a decision to move forward to Phase II is made.

Valuation: $33m or $4.45 per basic share

We have adjusted our valuation from $43m or $5.75 per basic share to $33m or $4.45 per basic share. The decrease in valuation is mostly attributable to lower estimates for the commercial business. We project that the company will need at least $45m in additional financing before profitability in 2024; this is up from $40m previously due to less forecast cash flow from the commercial business.

Slowing sales

The company reported Q119 revenues of $2.2m, down 15.8% compared with Q118 as both the biomedical and cosmetic businesses exhibited weakness. Biomedical revenues, which had been up 78.4% in 2018, were down 16.2% for the quarter and the reasons for the decline are unclear. The profitability of the biomedical business also declined as revenues fell but expenses grew. The segment provided $0.8m in profits in Q118, but only $0.3m this quarter. The cosmetics business continued its decline and sales were down 14.1% after being down 19.7% for 2018. The operating profit of the total commercial business decreased 73.2% to $0.2m in Q119. For the company as a whole (including its therapeutics development programs), the operating loss was $1.5m for the quarter, up 25.7% from $1.2m in the same quarter last year.

We have made some adjustments to our model, decreasing our 2019 revenue estimate for the commercial business from $13.0m to $9.9m and reducing our 2020 revenue estimate from $14.1m to $10.7m. This is due to an unexpected year over year decline in revenues for the biomedical business and the continued erosion of cosmetics, which we had expected to stabilize. We have kept SG&A roughly the same but reduced our 2019 R&D estimate to $2.0m from $2.5m due to company comments regarding costs following the completion of dosing for the Phase I trial. We may adjust them further in the future as we gain further insight into the PD development program and its future.

Exhibit 1
Exhibit 1

The company had $0.6m in cash on the balance sheet at the end of March. Subsequent to the quarter end, the company received an additional $0.8m in funds from its co-chairman and CEO, who already held a $1.0m promissory note from the company, due 15 January 2020. As part of the transaction, the old note has been surrendered and the company issued a new $1.8m promissory note to the CEO (accruing interest at 4.5% per year) with the same due date. We project that the company will need at least $45m in additional financing before profitability in 2024; this is up from $40m previously due to less forecast cash flow from the commercial business.

Valuation

We have adjusted our valuation from $43m or $5.75 per basic share to $33m or $4.45 per basic share. The decrease in valuation is mostly attributable to lower estimates for the commercial business. This was slightly offset by advancing our NPVs as well as the conversion of approximately $1.0m worth of a note payable into shares, which decreased the level of net debt.

Exhibit 2
Exhibit 2

One key risk to remember stems from the capital structure, which potentially creates sizeable dilution risk for minority investors. To date, ISCO has relied primarily on funds from management in the form of a combination of convertible preferred shares, warrants and options to fund its growth so that on a fully diluted basis management controls a significant portion of the company. While management has not converted the bulk of its sizeable holdings, investors need to consider the possibility of significant dilution risk at some point in the future. There remain approximately 15.5m potentially dilutive shares from 4.0m warrants, 5.5m options and 6.1m convertible preferred shares in addition to the 7.5m common shares outstanding. Also, investors should note that the convertible preferred shares are subject to anti-dilution provisions under certain circumstances, creating further dilution potential.

Exhibit 3
Exhibit 3

International Stem Cell: Q119 Results
 

Related Articles

International Stem Cell: Q119 Results

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email